🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Hormone-sensitive Prostate Cancer

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer NCT07216248Phase 21 site📍 Salt Lake City University of Utah · Tests: relugolix + ARPI, Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI, relugolix or androgen deprivati… A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) NCT07723248Phase 312 sites📍 Coral Springs📍 Jeffersonville📍 Holland ORIC Pharmaceuticals · Tests: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea NCT06334120n/a1 site📍 Multiple Locations Bayer · Tests: Darolutamide (Nubeqa, BAY1841788) Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer NCT04734730Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Abiraterone Acetate, Bicalutamide, Degarelix, Goserelin Acetate, Leuprolide Acetate ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer NCT03903835Phase 332 sites📍 Aalst📍 Antwerp📍 Bruges Karolinska Institutet · Tests: Enzalutamide Oral Capsule, Abiraterone Oral Tablet, Carboplatin, Cabazitaxel 60 mg Solution for Injection, Docetaxel In… Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) NCT07711002Phase 3210 sites📍 Hot Springs📍 Springdale📍 Beverly Hills AstraZeneca · Tests: Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) NCT06496581Phase 325 sites📍 Angers📍 Bordeaux📍 Brest UNICANCER · Tests: 177Lu-PMSA-617, Standard of Care Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). NCT05720130Phase 1, Phase 23 sites📍 Brisbane📍 Brisbane📍 Southport AdvanCell Pty Limited · Tests: [²¹²Pb]Pb-ADVC001 (Phase 1b), [²¹²Pb]Pb-ADVC001 (Phase 2a) Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response NCT06592924Phase 3395 sites📍 Anchorage📍 Anchorage📍 Anchorage Canadian Cancer Trials Group · Tests: Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer NCT07241416Phase 31 site📍 Beijing Jiangsu HengRui Medicine Co., Ltd. · Tests: Rezvilutamide Tablets, Enzalutamide Soft Capsules A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer NCT07005154Phase 254 sites📍 Huntsville📍 San Diego📍 Tampa Astellas Pharma Global Development, Inc. · Tests: ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial. NCT07333066Phase 356 sites📍 Bayonne📍 Bordeaux📍 Brest Alianza multidisciplinar para la investigación de los tumor… · Tests: Apalutamide (Erleada™) 60 mg or 240 mg tablets, Docetaxel Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer NCT04983095NA7 sites📍 Lund📍 Stockholm📍 Stockholm Karin Soderkvist · Tests: stereotactic body radiotherapy, androgen deprivation therapy, Radiotherapy A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer NCT06320067Phase 318 sites📍 Barnsley📍 Cambridge📍 Exeter University College, London · Tests: Stereotactic Ablative Body Radiotherapy (SABR), 177Lu-PSMA-617, Androgen Deprivation Therapy (ADT), Androgen Receptor S… Metastasis-directed Therapy for Oligorecurrent Prostate Cancer NCT05352178Phase 31 site📍 Leuven Universitaire Ziekenhuizen KU Leuven · Tests: Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany NCT07395804n/a1 site📍 Locations Bayer · Tests: darolutamide plus ADT treatment Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients NCT06350825Phase 31 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Cytoreductive prostatectomy or brachytherapy, ADT+second-generation antiandrogens ± chemotherapy FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial NCT06244004Phase 26 sites📍 Chicago📍 DeKalb📍 Geneva Northwestern University · Tests: Antiandrogen Therapy, Bone Scan, Computed Tomography, Cytotoxic Chemotherapy, FDG-Positron Emission Tomography Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer NCT07260435Phase 326 sites📍 Alkmaar📍 Amersfoort📍 Amsterdam Nick Beije · Tests: ADT plus only 12 months of ARPI, ADT plus continued ARPI Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN) NCT07290270n/a1 site📍 Shanghai Novartis Pharmaceuticals CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer NCT06306612NA1 site📍 Shanghai RenJi Hospital · Tests: Systemic Chemohormonal Therapy, Systemic Hormonal Therapy, Cytoreductive Prostatectomy, Postoperative Adjuvant Radiothe… Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006) NCT06429813NA1 site📍 Charlottesville Paul Viscuse · Tests: Home-Based Exercise Intervention - Walking, Home-Based Exercise Intervention - HIIT Cycling Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial NCT07650240Phase 21 site📍 Rochester Mayo Clinic · Tests: Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate, Lutetium Lu 177 Vipivotide Tetraxetan, Prednisone Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment NCT05649943NA3 sites📍 Milan📍 Milan📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: APA + ADT, Local Treatmetn RT or RP Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC NCT06177015Phase 31 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Darolutamide continuous, Darolutamide intermittent A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer NCT04729114Phase 125 sites📍 Tucson📍 Anaheim📍 Santa Rosa Astellas Pharma Global Development, Inc. · Tests: PRL-02 injection, prednisone, dexamethasone, enzalutamide JUR-003 in Adult Patients With Metastatic Prostate Cancer NCT07824349Phase 14 sites📍 Grand Rapids📍 Lake Success📍 Nashville Juri Biosciences, Inc. · Tests: JUR-003 Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial NCT07466498Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) NCT06654336Phase 25 sites📍 Hamilton📍 Ottawa📍 Toronto Ontario Clinical Oncology Group (OCOG) · Tests: Recurrence-directed therapy (RDT), ELIGARD 22.5mg Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer NCT06582628Phase 219 sites📍 Bordeaux📍 Brest📍 Lille Fundacion Oncosur · Tests: Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy